trial · primary record
Orelabrutinib and obinutuzumab
Marginal Zone Lymphoma
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 74 |
| Primary completion | 2029-06-21 |
| Primary endpoint | the complete response rate |
| Registry ID | NCT06513234 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:53.777Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06513234
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.